Autolus Therapeutics plc SEC filings AUTL
Autolus Therapeutics plc has 336 filings in SEC EDGAR's recent list, going back to Feb 9, 2018. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 3, 2026 | Sep 1, 2026 |
| 144 | Notice of proposed sale | Sep 2, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 28, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 3 | Initial insider ownership | Mar 23, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Dec 3, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 6, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 25, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 12, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 4, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 8, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 25, 2024 | — |
| 144 | Notice of proposed sale | Sep 16, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 21, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 25, 2024 | — |
| SC 13D | Ownership over 5% (active) | Feb 21, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 31, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jul 10, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Mar 20, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Dec 19, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 13, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Dec 13, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 5, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Dec 17, 2021 | — |
| SC 13D | Ownership over 5% (active) | Nov 16, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 23, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 17, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 8, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 13, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 3, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 20, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 6, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 15, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Apr 22, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2020 | — |
| SC 13D | Ownership over 5% (active) | Jan 24, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 9, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 9, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Sep 20, 2019 | — |
| SC 13G | Ownership over 5% (passive) | Sep 16, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Sep 9, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Aug 8, 2019 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2019 | — |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 10, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Sep 13, 2018 | — |
| SC 13G | Ownership over 5% (passive) | Jul 10, 2018 | — |
| SC 13G | Ownership over 5% (passive) | Jul 10, 2018 | — |
| SC 13D | Ownership over 5% (active) | Jul 6, 2018 | — |
Showing 105 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AUTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- London, United Kingdom
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1730463
- Former names
- Autolus Therapeutics Ltd (until Jun 8, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.